The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos (mavacamten) to treat adolescents aged 12 to under 18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn.
Eli Lilly and Company has entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue), worldwide excluding Korea.
Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer medications.
SK bioscience has signed a vaccine technology transfer and manufacturing agreement with Colombia’s state-owned pharmaceutical company VECOL, becoming part of the country’s $260m vaccine localisation initiative.
Scientists at the University of Edinburgh have developed a new cell therapy aiming to provide a potential alternative to liver transplants for patients with advanced liver disease.
AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab deruxtecan) to treat metastatic triple-negative breast cancer (TNBC).
Concept Life Sciences has signed a strategic partnership with OpenBench to deliver success-based drug discovery services targeted at early-stage biotech companies.
Gilead Sciences has concluded its acquisition of Tubulis, a Germany-based biotechnology company developing next-generation antibody-drug conjugates (ADCs), in a transaction valued at up to $5bn.
FUJIFILM Cellular Dynamics has opened a new headquarters and induced pluripotent stem cell (iPSC) manufacturing facility in Madison, Wisconsin, US.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.